inorganic hydroxy compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	inorganic hydroxy compound	go back to main search page
Accession:	CHEBI:52625	browse the term
Synonyms:	related_synonym:	inorganic hydroxides

show annotations for term's descendants Sort by:
Rat (766) Mouse (780) Human (781) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (4) Green Monkey (0) Naked Mole-rat (0) All
Genes (780)

ammonium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

FBJ osteosarcoma oncogene

increases expression

Ammonium Hydroxide results in increased expression of FOS protein

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

heme oxygenase 1

increases expression
multiple interactions

Ammonium Hydroxide results in increased expression of HMOX1 mRNA
Ammonium Hydroxide results in increased expression of and results in increased activity of HMOX1 protein

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

aldo-keto reductase family 1, member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

C-X-C motif chemokine ligand 15

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of CXCL8 protein

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051

G

cytochrome P450, family 7, subfamily a, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 8, subfamily b, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371

G

fibroblast growth factor 15

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690

G

glucose-6-phosphate dehydrogenase X-linked

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

glutamic-oxaloacetic transaminase 1, soluble

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 51, alpha subunit

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr16:32,294,396...32,306,697
Ensembl chr16:32,293,322...32,306,697

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

calcium dihydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alkaline phosphatase, liver/bone/kidney

increases expression

Calcium Hydroxide results in increased expression of ALPL mRNA

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

collagen, type I, alpha 1

increases expression

Calcium Hydroxide results in increased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

estrogen receptor 1 (alpha)

increases expression

Calcium Hydroxide results in increased expression of ESR1 mRNA

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

polymerase (DNA directed), gamma

affects expression

Calcium Hydroxide affects the expression of POLG mRNA

NCBI chr 7:79,095,979...79,117,659
Ensembl chr 7:79,095,979...79,116,110

G

polymerase (DNA directed), gamma 2, accessory subunit

affects expression

Calcium Hydroxide affects the expression of POLG2 mRNA

NCBI chr11:106,659,030...106,670,363
Ensembl chr11:106,659,079...106,670,363

G

transcription factor A, mitochondrial

affects expression

Calcium Hydroxide affects the expression of TFAM mRNA

NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110

G

transient receptor potential cation channel, subfamily V, member 1

increases expression

Calcium Hydroxide results in increased expression of TRPV1 mRNA

NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068

carbidopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated X protein

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]

PMID:34560070 PMID:35202708

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

PMID:34560070 PMID:35202708

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

caspase 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

PMID:34560070 PMID:35202708

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]

PMID:34560070 PMID:35202708

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Carbidopa

NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602

G

dopa decarboxylase

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA]
Carbidopa binds to and results in decreased activity of DDC protein

PMID:35151785 PMID:35202708

NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144

G

dynamin 1-like

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]

NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823

G

fission, mitochondrial 1

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]

NCBI chr 5:136,982,129...136,995,088
Ensembl chr 5:136,982,129...136,995,088

G

glutamic pyruvic transaminase, soluble

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

interleukin 1 beta

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

monoamine oxidase A

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]

PMID:34560070 PMID:35202708

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

mitofusin 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]

NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388

G

ATP synthase 6, mitochondrial

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]

NCBI chr MT:7,927...8,607
Ensembl chr MT:7,927...8,607

G

cytochrome b, mitochondrial

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]

NCBI chr MT:14,145...15,288
Ensembl chr MT:14,145...15,288

G

NADH dehydrogenase 1, mitochondrial

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]

NCBI chr MT:2,751...3,707
Ensembl chr MT:2,751...3,707

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

synuclein, alpha

multiple interactions

[Levodopa co-treated with Carbidopa] inhibits the reaction [Reserpine results in increased expression of SNCA protein]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

signal transducer and activator of transcription 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

tumor necrosis factor

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tryptophan hydroxylase 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]

NCBI chr 7:46,294,065...46,321,961
Ensembl chr 7:46,294,065...46,321,961

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family C member 4

increases transport

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

dihydrofolate reductase

decreases activity

Ceftazidime results in decreased activity of DHFR protein

NCBI chr13:92,491,291...92,525,561
Ensembl chr13:92,491,234...92,525,561

G

heat shock factor 1

decreases activity

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113

G

interleukin 10

multiple interactions

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

cilazapril monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects response to substance

ACE gene polymorphism affects the susceptibility to Cilazapril

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

adiponectin, C1Q and collagen domain containing

increases expression

Cilazapril results in increased expression of ADIPOQ protein

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

angiotensin II receptor, type 1a

multiple interactions

[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

angiotensin II receptor, type 2

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]

NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403

G

fibroblast growth factor 2

decreases expression

Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

natriuretic peptide type A

affects secretion
multiple interactions

Cilazapril affects the secretion of NPPA protein
[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein

NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536

G

renin 1 structural

increases activity

Cilazapril results in increased activity of REN protein

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

solute carrier family 15 (oligopeptide transporter), member 1

multiple interactions

Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr14:121,697,033...121,742,666
Ensembl chr14:121,697,033...121,742,664

G

solute carrier family 15 (H+/peptide transporter), member 2

multiple interactions

Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr16:36,570,523...36,605,506
Ensembl chr16:36,570,539...36,605,324

G

transforming growth factor, beta 1

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

dideuterium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymoma viral proto-oncogene 1

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

thymoma viral proto-oncogene 2

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT2 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT2 protein]

NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251

G

thymoma viral proto-oncogene 3

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT3 protein]

NCBI chr 1:176,847,642...177,091,688
Ensembl chr 1:176,847,639...177,085,769

G

BCL2-associated X protein

increases expression

Deuterium Oxide results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

beclin 1, autophagy related

increases expression
multiple interactions

Deuterium Oxide results in increased expression of BECN1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of BECN1 protein]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

caspase 3

increases cleavage

Deuterium Oxide results in increased cleavage of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of MTOR protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of MTOR protein]

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of PIK3R1 protein]

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Antimony Potassium Tartrate results in decreased expression of A2M mRNA

NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186

G

ATP-binding cassette, sub-family C member 1

affects response to substance
decreases response to substance
increases secretion
multiple interactions

ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in increased secretion of Antimony Potassium Tartrate
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]

PMID:10025956 PMID:10348353 PMID:11278867 PMID:12018890 PMID:12731862

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family member 2

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA

PMID:11408547 PMID:32076005

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC3 mRNA

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

acid phosphatase 2, lysosomal

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA

NCBI chr 2:91,033,157...91,044,443
Ensembl chr 2:91,033,230...91,044,443

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACSL1 mRNA

NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088

G

adrenomedullin

increases expression

Antimony Potassium Tartrate results in increased expression of ADM mRNA

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

aldo-keto reductase family 1 member B

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of AKR1B1 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B1 mRNA

PMID:17547211 PMID:28713220

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

aldo-keto reductase family 1, member B10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA

PMID:28713220 PMID:32076005

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

aldo-keto reductase family 1, member C18

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA

PMID:28713220 PMID:32076005

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C21

increases expression

Antimony Potassium Tartrate results in increased expression of AKR1C2 protein

NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540

G

aldehyde dehydrogenase family 3, subfamily A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ALDH3A2 mRNA

NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr19:4,008,733...4,022,419
Ensembl chr19:4,008,645...4,022,103

G

aldehyde dehydrogenase family 6, subfamily A1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ALDH6A1 mRNA

NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778

G

aldolase C, fructose-bisphosphate

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOC mRNA

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

androgen receptor

increases phosphorylation

Antimony Potassium Tartrate results in increased phosphorylation of AR protein

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ATPase, Ca++ transporting, plasma membrane 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ATP2B1 mRNA

NCBI chr10:98,750,243...98,862,005
Ensembl chr10:98,750,268...98,862,005

G

alpha-2-glycoprotein 1, zinc

decreases expression

Antimony Potassium Tartrate results in decreased expression of AZGP1 mRNA

NCBI chr 5:137,979,783...137,988,495
Ensembl chr 5:137,979,782...137,988,495

G

BarH-like homeobox 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BARX2 mRNA

NCBI chr 9:31,757,340...31,824,581
Ensembl chr 9:31,757,340...31,824,758

G

BCL2-associated X protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

bone morphogenetic protein 6

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

basic transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTF3 mRNA

NCBI chr13:98,446,405...98,453,514
Ensembl chr13:98,446,404...98,453,514

G

BTG anti-proliferation factor 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTG2 mRNA

NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858

G

calmodulin 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of CALML5 mRNA

NCBI chr13:3,887,757...3,888,671
Ensembl chr13:3,887,757...3,888,673

G

calreticulin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CALR mRNA

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

caspase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased cleavage of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

carbonyl reductase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CBR1 mRNA

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

cyclin B2

increases expression

Antimony Potassium Tartrate results in increased expression of CCNB2 mRNA

NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829

G

cyclin D1

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin dependent kinase inhibitor 1A

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 2B

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CDKN2B mRNA

NCBI chr 4:89,224,526...89,229,269
Ensembl chr 4:89,224,536...89,229,276

G

cyclin dependent kinase inhibitor 3

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN3 mRNA

NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CEBPA mRNA

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

G

complement factor B

decreases expression

Antimony Potassium Tartrate results in decreased expression of CFB mRNA

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

CDC28 protein kinase regulatory subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of CKS2 mRNA

NCBI chr13:51,799,268...51,804,698
Ensembl chr13:51,799,268...51,804,696

G

calmegin

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLGN mRNA

NCBI chr 8:84,116,454...84,155,181
Ensembl chr 8:84,116,496...84,155,181

G

cleft lip and palate associated transmembrane protein 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLPTM1 mRNA

NCBI chr 7:19,365,505...19,398,955
Ensembl chr 7:19,365,496...19,398,958

G

cellular nucleic acid binding protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CNBP mRNA

NCBI chr 6:87,819,597...87,828,088
Ensembl chr 6:87,819,597...87,828,088

G

cAMP responsive element binding protein 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]

PMID:32920012 PMID:34571074

NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CYP1B1 mRNA

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

DAZ associated protein 1

increases expression

Antimony Potassium Tartrate results in increased expression of DAZAP1 mRNA

NCBI chr10:80,097,168...80,124,242
Ensembl chr10:80,097,320...80,124,242

G

decapping mRNA 1A

increases expression

Antimony Potassium Tartrate results in increased expression of DCP1A mRNA

NCBI chr14:30,201,613...30,249,013
Ensembl chr14:30,201,492...30,249,020

G

dehydrogenase/reductase 9

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DHRS9 mRNA

NCBI chr 2:69,210,806...69,233,430
Ensembl chr 2:69,210,789...69,234,877

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DNAJB1 mRNA

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of DNAJB4 mRNA

NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939

G

desmocollin 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]

PMID:28713220 PMID:32076005

NCBI chr18:20,216,528...20,247,830
Ensembl chr18:20,217,241...20,247,928

G

desmoglein 1 alpha

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:20,443,982...20,476,407
Ensembl chr18:20,443,868...20,476,407

G

dystonin

decreases expression

Antimony Potassium Tartrate results in decreased expression of DST protein

NCBI chr 1:33,946,969...34,347,743
Ensembl chr 1:33,947,306...34,347,742

G

dual oxidase 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA
Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr 2:122,143,525...122,178,454
Ensembl chr 2:122,146,153...122,178,453

G

dual oxidase maturation factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of DUOXA1 mRNA

NCBI chr 2:122,134,012...122,144,255
Ensembl chr 2:122,132,672...122,144,211

G

dual specificity phosphatase 1

increases expression

Antimony Potassium Tartrate results in increased expression of DUSP1 mRNA

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 12

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]

NCBI chr 1:170,701,756...170,713,109
Ensembl chr 1:170,701,067...170,713,109

G

dual specificity phosphatase 2

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296

G

early growth response 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EGR3 mRNA

NCBI chr14:70,314,766...70,320,062
Ensembl chr14:70,314,652...70,320,063

G

ets homologous factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EHF mRNA

NCBI chr 2:103,093,776...103,133,620
Ensembl chr 2:103,093,778...103,133,623

G

E74-like factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ELF3 mRNA

NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306

G

Eph receptor A1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA1 protein

NCBI chr 6:42,335,421...42,350,249
Ensembl chr 6:42,335,421...42,350,202

G

Eph receptor A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA2 protein

NCBI chr 4:141,028,532...141,056,695
Ensembl chr 4:141,028,551...141,056,695

G

epoxide hydrolase 1, microsomal

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of EPHX1 mRNA

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

coagulation factor V

decreases expression

Antimony Potassium Tartrate results in decreased expression of F5 mRNA

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

fatty acid binding protein 5, epidermal

decreases expression

Antimony Potassium Tartrate results in decreased expression of FABP5 mRNA

NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667

G

farnesyl diphosphate farnesyl transferase 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDFT1 mRNA

NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027

G

farnesyl diphosphate synthetase

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDPS mRNA

NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266

G

fibroblast growth factor receptor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FGFR3 mRNA

NCBI chr 5:33,879,068...33,894,412
Ensembl chr 5:33,879,018...33,894,412

G

filaggrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of FLG mRNA
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

PMID:28713220 PMID:32076005

NCBI chr 3:93,180,853...93,200,996
Ensembl chr 3:93,180,830...93,200,993

G

FBJ osteosarcoma oncogene

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOS mRNA

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

fos-like antigen 1

increases expression

Antimony Potassium Tartrate results in increased expression of FOSL1 mRNA

NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974

G

forkhead box Q1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOXQ1 mRNA

NCBI chr13:31,742,153...31,744,959
Ensembl chr13:31,740,117...31,744,959

G

ferritin heavy polypeptide 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA

PMID:28713220 PMID:32076005

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTL mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA

PMID:28713220 PMID:32076005

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

glucose-6-phosphate dehydrogenase X-linked

increases expression

Antimony Potassium Tartrate results in increased expression of G6PD mRNA; Antimony Potassium Tartrate results in increased expression of G6PD protein

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of GAPDH mRNA

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA

PMID:28713220 PMID:32076005

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLM mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA

PMID:28713220 PMID:32076005

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Antimony Potassium Tartrate results in increased expression of GCNT3 mRNA

NCBI chr 9:69,938,777...69,947,172
Ensembl chr 9:69,938,778...69,945,370

G

glial fibrillary acidic protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein
666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

gamma-glutamyltransferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GGT1 mRNA

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

growth hormone inducible transmembrane protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of GHITM mRNA

NCBI chr14:36,842,401...36,857,279
Ensembl chr14:36,842,049...36,857,229

G

galactosidase, alpha

increases expression

Antimony Potassium Tartrate results in increased expression of GLA mRNA

NCBI chr X:133,488,912...133,501,707
Ensembl chr X:133,488,898...133,501,874

G

glutaredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GLRX mRNA

NCBI chr13:75,988,004...75,998,270
Ensembl chr13:75,987,987...75,998,273

G

glutathione peroxidase 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GPX2 mRNA

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

grainyhead like transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of GRHL1 mRNA

NCBI chr12:24,622,234...24,667,390
Ensembl chr12:24,622,282...24,667,390

G

glutathione S-transferase omega 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GSTO1 mRNA

NCBI chr19:47,843,412...47,853,229
Ensembl chr19:47,843,409...47,853,229

G

GTP binding protein 6 (putative)

increases expression

Antimony Potassium Tartrate results in increased expression of GTPBP6 mRNA

NCBI chr 5:110,251,842...110,256,063
Ensembl chr 5:110,251,841...110,256,063

G

H4 clustered histone 14

increases expression

Antimony Potassium Tartrate results in increased expression of H4C3 mRNA

NCBI chr 3:96,170,250...96,170,633
Ensembl chr 3:96,168,998...96,170,627

G

helicase-like transcription factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HLTF mRNA

NCBI chr 3:20,111,959...20,172,655
Ensembl chr 3:20,111,975...20,172,654

G

high mobility group AT-hook 1

increases expression

Antimony Potassium Tartrate results in increased expression of HMGA1 mRNA

NCBI chr17:27,774,798...27,782,649
Ensembl chr17:27,775,471...27,782,648

G

heme oxygenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

HOP homeobox

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of HOPX mRNA

NCBI chr 5:77,234,831...77,262,970
Ensembl chr 5:77,234,835...77,262,968

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B2 mRNA

NCBI chr 8:118,427,752...118,485,767
Ensembl chr 8:118,428,643...118,485,766

G

hydroxysteroid (17-beta) dehydrogenase 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B7 mRNA

NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810

G

heat shock protein 1A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA1A mRNA

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPB8 mRNA

NCBI chr 5:116,546,550...116,560,923
Ensembl chr 5:116,546,550...116,560,923

G

HIV-1 Tat interactive protein 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HTATIP2 mRNA

NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723

G

inhibitor of DNA binding 1, HLH protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ID1 mRNA

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

immediate early response 2

increases expression

Antimony Potassium Tartrate results in increased expression of IER2 mRNA

NCBI chr 8:85,387,960...85,389,481
Ensembl chr 8:85,387,960...85,389,483

G

interferon-related developmental regulator 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of IFRD1 mRNA

NCBI chr12:40,253,128...40,273,184
Ensembl chr12:40,251,566...40,298,503

G

IKAROS family zinc finger 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IKZF2 mRNA

NCBI chr 1:69,570,382...69,726,510
Ensembl chr 1:69,570,373...69,726,404

G

interleukin 1 receptor antagonist

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IL1RN mRNA

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

G

interleukin 4

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

inhibitor of growth family, member 3

increases expression

Antimony Potassium Tartrate results in increased expression of ING3 mRNA

NCBI chr 6:21,948,002...21,976,037
Ensembl chr 6:21,949,570...21,976,037

G

integrin beta 3 binding protein (beta3-endonexin)

increases expression

Antimony Potassium Tartrate results in increased expression of ITGB3BP mRNA

NCBI chr 4:99,655,643...99,717,403
Ensembl chr 4:99,653,639...99,787,010

G

inter-alpha trypsin inhibitor, heavy chain 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of ITIH3 mRNA

NCBI chr14:30,630,529...30,645,748
Ensembl chr14:30,630,529...30,645,717

G

involucrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA

PMID:28713220 PMID:32076005

NCBI chr 3:92,478,206...92,481,097
Ensembl chr 3:92,478,209...92,481,042

G

Kruppel-like transcription factor 5

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KLF5 mRNA

NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472

G

Kruppel-like transcription factor 6

increases expression

Antimony Potassium Tartrate results in increased expression of KLF6 mRNA

NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393

G

keratin 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]

NCBI chr15:101,753,861...101,759,221
Ensembl chr15:101,753,861...101,759,229

G

keratin 10

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]

PMID:28713220 PMID:32076005

NCBI chr11:99,276,080...99,288,631
Ensembl chr11:99,276,080...99,280,190

G

keratinocyte differentiation associated protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of KRTDAP mRNA

NCBI chr 7:30,487,330...30,490,514
Ensembl chr 7:30,487,321...30,490,522

G

lysosomal acid lipase A

decreases expression

Antimony Potassium Tartrate results in decreased expression of LIPA mRNA

NCBI chr19:34,469,716...34,504,874
Ensembl chr19:34,469,718...34,504,874

G

loricrin cornified envelope precursor protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of LORICRIN mRNA

NCBI chr 3:91,987,578...91,990,447
Ensembl chr 3:91,987,578...91,990,449

G

leucine-rich repeats and immunoglobulin-like domains 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA

NCBI chr 6:94,581,510...94,677,205
Ensembl chr 6:94,581,510...94,677,139

G

lanosterol synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of LSS mRNA

NCBI chr10:76,367,303...76,392,973
Ensembl chr10:76,367,422...76,392,972

G

v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)

increases expression

Antimony Potassium Tartrate results in increased expression of MAFF mRNA

NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276

G

mannosidase, alpha, class 1A, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MAN1A2 mRNA

NCBI chr 3:100,469,519...100,592,789
Ensembl chr 3:100,469,524...100,592,819

G

monoamine oxidase A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

mitogen-activated protein kinase kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MAP2K1 mRNA

NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913

G

mitogen-activated protein kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

minichromosome maintenance complex component 2

increases expression

Antimony Potassium Tartrate results in increased expression of MCM2 mRNA

NCBI chr 6:88,860,456...88,875,762
Ensembl chr 6:88,860,456...88,875,762

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression

Antimony Potassium Tartrate results in increased expression of ME1 mRNA

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

mannoside acetylglucosaminyltransferase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MGAT2 mRNA

NCBI chr12:69,230,932...69,233,547
Ensembl chr12:69,230,931...69,233,544

G

microsomal glutathione S-transferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MGST1 mRNA

NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753

G

metallothionein 1

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of MT1X mRNA
Antimony Potassium Tartrate results in increased expression of MT1X mRNA

PMID:17547211 PMID:28713220

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

increases expression

Antimony Potassium Tartrate results in increased expression of MT2A mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate
MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate

NCBI chr12:12,986,094...12,991,837
Ensembl chr12:12,986,094...12,991,915

G

N-myc downstream regulated gene 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NDRG2 mRNA

NCBI chr14:52,142,738...52,151,463
Ensembl chr14:52,142,728...52,151,615

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NFKB2 mRNA

NCBI chr19:46,285,478...46,300,839
Ensembl chr19:46,292,759...46,300,824

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

decreases expression

Antimony Potassium Tartrate results in decreased expression of NFKBIA mRNA

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

NK3 homeobox 1

multiple interactions
increases expression

bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]
Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein

NCBI chr14:69,428,141...69,432,107
Ensembl chr14:69,428,087...69,432,111

G

nitric oxide synthase 2, inducible

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein
666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA

PMID:28713220 PMID:32076005

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

N-ribosyldihydronicotinamide quinone reductase 2

increases expression

Antimony Potassium Tartrate results in increased expression of NQO2 mRNA

NCBI chr13:34,148,642...34,172,448
Ensembl chr13:34,148,670...34,172,426

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

amplified in osteosarcoma

decreases expression

Antimony Potassium Tartrate results in decreased expression of OS9 mRNA

NCBI chr10:126,928,880...126,957,029
Ensembl chr10:126,931,519...126,957,000

G

oncostatin M

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]

NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026

G

pre B cell leukemia homeobox 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PBX1 mRNA

NCBI chr 1:167,946,933...168,259,898
Ensembl chr 1:167,946,933...168,259,839

G

proliferating cell nuclear antigen

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PCNA protein

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

protein disulfide isomerase associated 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of PDIA4 mRNA

NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364

G

progastricsin (pepsinogen C)

decreases expression

Antimony Potassium Tartrate results in decreased expression of PGC mRNA

NCBI chr17:48,037,767...48,045,403
Ensembl chr17:48,037,767...48,045,407

G

phosphogluconate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of PGD protein

NCBI chr 4:149,234,448...149,251,162
Ensembl chr 4:149,234,448...149,251,228

G

phosphoglucomutase 1

increases expression

Antimony Potassium Tartrate results in increased expression of PGM1 mRNA

NCBI chr 4:99,786,648...99,844,491
Ensembl chr 4:99,786,611...99,844,491

G

phosphoglucomutase 3

increases expression

Antimony Potassium Tartrate results in increased expression of PGM3 mRNA

NCBI chr 9:86,423,997...86,453,927
Ensembl chr 9:86,436,430...86,453,895

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R1 mRNA

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

G

phosphoinositide-3-kinase regulatory subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R2 mRNA

NCBI chr 8:71,220,820...71,229,356
Ensembl chr 8:71,220,820...71,229,357

G

pirin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PIR mRNA

NCBI chr X:163,052,427...163,156,009
Ensembl chr X:163,052,367...163,156,007

G

paired-like homeodomain transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PITX1 mRNA

NCBI chr13:55,972,857...55,984,002
Ensembl chr13:55,972,864...55,984,005

G

promyelocytic leukemia

affects localization
multiple interactions
increases degradation

Antimony Potassium Tartrate affects the localization of PML protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased degradation of PML protein mutant form

NCBI chr 9:58,125,359...58,157,077
Ensembl chr 9:58,125,359...58,157,069

G

peptidyl prolyl isomerase H

increases expression

Antimony Potassium Tartrate results in increased expression of PPIH mRNA

NCBI chr 4:119,157,207...119,177,720
Ensembl chr 4:119,157,207...119,177,743

G

peroxiredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PRDX1 mRNA

NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019

G

phosphoserine phosphatase

decreases expression

Antimony Potassium Tartrate results in decreased expression of PSPH mRNA

NCBI chr 5:129,842,622...129,864,318
Ensembl chr 5:129,842,622...129,864,513

G

pituitary tumor-transforming gene 1

increases expression

Antimony Potassium Tartrate results in increased expression of PTTG1 mRNA

NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078

G

retinoic acid receptor, alpha

increases degradation

Antimony Potassium Tartrate results in increased degradation of RARA protein mutant form

NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768

G

RNA binding protein gene with multiple splicing

increases expression

Antimony Potassium Tartrate results in increased expression of RBPMS mRNA

NCBI chr 8:34,272,671...34,419,925
Ensembl chr 8:34,272,671...34,419,891

G

replication factor C (activator 1) 2

increases expression

Antimony Potassium Tartrate results in increased expression of RFC2 mRNA

NCBI chr 5:134,611,544...134,627,182
Ensembl chr 5:134,610,220...134,630,659

G

ribonuclease H2, large subunit

increases expression

Antimony Potassium Tartrate results in increased expression of RNASEH2A mRNA

NCBI chr 8:85,683,239...85,694,498
Ensembl chr 8:85,683,239...85,696,396

G

ribonuclease/angiogenin inhibitor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RNH1 protein

NCBI chr 7:140,740,239...140,752,764
Ensembl chr 7:140,740,239...140,752,770

G

repetin

decreases expression

Antimony Potassium Tartrate results in decreased expression of RPTN mRNA

NCBI chr 3:93,301,006...93,306,749
Ensembl chr 3:93,301,006...93,306,749

G

ryanodine receptor 1, skeletal muscle

decreases expression

Antimony Potassium Tartrate results in decreased expression of RYR1 mRNA

NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604

G

S100 calcium binding protein A2

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A2 mRNA

NCBI chr 3:90,497,554...90,498,815
Ensembl chr 3:90,467,670...90,498,838

G

S100 calcium binding protein A8 (calgranulin A)

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

G

S100 calcium binding protein A9 (calgranulin B)

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein

NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028

G

stearoyl-Coenzyme A desaturase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SCD mRNA

NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303

G

selenophosphate synthetase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SEPHS2 mRNA

NCBI chr 7:126,871,051...126,873,231
Ensembl chr 7:126,871,051...126,873,227

G

serine (or cysteine) peptidase inhibitor, clade B, member 1a

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINB1 mRNA

NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168

G

serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINC1 mRNA

NCBI chr 1:160,806,153...160,830,113
Ensembl chr 1:160,806,155...160,833,433

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

salt inducible kinase 1

increases expression

Antimony Potassium Tartrate results in increased expression of SIK1 mRNA

NCBI chr17:32,063,222...32,074,808
Ensembl chr17:32,063,224...32,074,778

G

solute carrier family 2 (facilitated glucose transporter), member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SLC2A3 mRNA

NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Antimony Potassium Tartrate results in increased expression of SNRPA mRNA

NCBI chr 7:26,886,431...26,895,696
Ensembl chr 7:26,886,430...26,895,696

G

superoxide dismutase 1, soluble

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SOD1 mRNA

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

small proline-rich protein 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein

NCBI chr 3:92,391,261...92,393,188
Ensembl chr 3:92,391,259...92,393,202

G

small proline-rich protein 1B

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein

NCBI chr 3:92,344,115...92,346,124
Ensembl chr 3:92,344,116...92,346,096

G

small proline-rich protein 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein

NCBI chr 3:92,363,809...92,366,027
Ensembl chr 3:92,363,809...92,366,027

G

squalene epoxidase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SQLE mRNA

NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041

G

sequestosome 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SQSTM1 mRNA

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

serine and arginine-rich splicing factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF1 mRNA

NCBI chr11:87,937,325...87,944,583
Ensembl chr11:87,938,199...87,944,581

G

serine and arginine-rich splicing factor 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF5 mRNA

NCBI chr12:80,992,308...80,997,277
Ensembl chr12:80,992,278...80,997,281

G

sulfiredoxin 1 homolog (S. cerevisiae)

increases expression

Antimony Potassium Tartrate results in increased expression of SRXN1 mRNA

NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296

G

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of ST6GALNAC4 mRNA

NCBI chr 2:32,477,100...32,489,710
Ensembl chr 2:32,477,107...32,489,710

G

signal transducer and activator of transcription 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA

NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024

G

sulfotransferase family, cytosolic, 1C, member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1C3 mRNA

NCBI chr17:54,268,643...54,297,659
Ensembl chr17:54,268,643...54,297,702

G

sulfotransferase family 1E, member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1E1 mRNA

NCBI chr 5:87,723,827...87,739,470
Ensembl chr 5:87,723,828...87,739,453

G

sulfotransferase family, cytosolic, 2B, member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT2B1 mRNA

NCBI chr 7:45,379,405...45,409,096
Ensembl chr 7:45,379,407...45,434,093

G

small ubiquitin-like modifier 1

affects localization
multiple interactions

Antimony Potassium Tartrate affects the localization of SUMO1 protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]

NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993

G

TAR DNA binding protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of TARDBP mRNA

NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476

G

transglutaminase 1, K polypeptide

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TGM1 mRNA

NCBI chr14:55,937,466...55,951,378
Ensembl chr14:55,937,466...55,951,383

G

tumor necrosis factor, alpha-induced protein 3

increases expression

Antimony Potassium Tartrate results in increased expression of TNFAIP3 mRNA

NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405

G

tumor necrosis factor (ligand) superfamily, member 10

decreases expression

Antimony Potassium Tartrate results in decreased expression of TNFSF10 mRNA

NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576

G

transducer of ErbB-2.1

decreases expression

Antimony Potassium Tartrate results in decreased expression of TOB1 mRNA

NCBI chr11:94,100,668...94,106,321
Ensembl chr11:94,102,280...94,106,321

G

triosephosphate isomerase 1

increases expression

Antimony Potassium Tartrate results in increased expression of TPI1 mRNA

NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259

G

transformation related protein 63

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TP63 mRNA

NCBI chr16:25,502,513...25,710,842
Ensembl chr16:25,502,513...25,710,852

G

TSC22 domain family, member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TSC22D3 mRNA

NCBI chr X:139,440,277...139,501,257
Ensembl chr X:139,440,277...139,501,408

G

tetraspanin 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of TSPAN7 mRNA

NCBI chr X:10,351,355...10,462,843
Ensembl chr X:10,351,397...10,462,844

G

tuftelin 1

increases expression

Antimony Potassium Tartrate results in increased expression of TUFT1 mRNA

NCBI chr 3:94,520,060...94,566,179
Ensembl chr 3:94,520,064...94,566,179

G

thioredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXN mRNA

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

G

thioredoxin reductase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

G

thymidylate synthase

increases expression

Antimony Potassium Tartrate results in increased expression of TYMS mRNA

NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615

G

ubiquitin-conjugating enzyme E2C

increases expression

Antimony Potassium Tartrate results in increased expression of UBE2C mRNA

NCBI chr 2:164,611,849...164,614,822
Ensembl chr 2:164,611,818...164,620,742

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

ZW10 interactor

increases expression

Antimony Potassium Tartrate results in increased expression of ZWINT mRNA

NCBI chr10:72,490,678...72,510,796
Ensembl chr10:72,490,677...72,510,796

diprotium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]

NCBI chr 8:106,293,327...106,306,477
Ensembl chr 8:106,293,330...106,364,025

G

thymoma viral proto-oncogene 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of AKT1 mRNA

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

aquaporin 1

increases transport
multiple interactions

AQP1 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP1 protein results in increased transport of Water]

PMID:7528928 PMID:8457558 PMID:10559675 PMID:11035042 PMID:11078688 More...

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 11

multiple interactions
increases transport

Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]

NCBI chr 7:97,375,586...97,387,454
Ensembl chr 7:97,373,213...97,387,496

G

aquaporin 2

increases expression

Water deficiency results in increased expression of AQP2 mRNA

NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428

G

aquaporin 3

multiple interactions
increases expression
increases transport

Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]]
Water deficiency results in increased expression of AQP3 mRNA; Water deficiency results in increased expression of AQP3 protein
Copper Sulfate inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]

PMID:9124401 PMID:9374739 PMID:15462210 PMID:22687538

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

aquaporin 4

increases transport
increases response to substance
increases expression
affects transport

AQP4 protein results in increased transport of Water
AQP4 protein results in increased susceptibility to Water
Water deficiency results in increased expression of AQP4 mRNA
AQP4 protein affects the transport of Water

PMID:7528931 PMID:15462210 PMID:20815926 PMID:21251984

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

aquaporin 7

affects transport
increases transport

AQP7 protein affects the transport of Water
AQP7 protein results in increased transport of Water

PMID:9252401 PMID:18059526

NCBI chr 4:41,033,074...41,048,237
Ensembl chr 4:41,033,074...41,048,139

G

aquaporin 8

multiple interactions
increases transport
affects transport

Copper affects the reaction [AQP8 protein affects the transport of Water]; Mercury affects the reaction [AQP8 protein affects the transport of Water]
AQP8 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP8 protein results in increased transport of Water]

PMID:18059526 PMID:19840149

NCBI chr 7:123,061,517...123,067,226
Ensembl chr 7:123,061,514...123,067,227

G

aquaporin 9

multiple interactions
increases transport
affects transport

CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; Mercuric Chloride inhibits the reaction [AQP9 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

PMID:9514918 PMID:9733774 PMID:10205677 PMID:12606488 PMID:21259319 More...

NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964

G

arginine vasopressin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of AVP protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474

G

B cell leukemia/lymphoma 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of BCL2 mRNA

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

beclin 1, autophagy related

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

BCL2/adenovirus E1B interacting protein 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]

NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248

G

CART prepropeptide

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA; [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr13:100,034,991...100,037,191
Ensembl chr13:100,034,997...100,037,599

G

caspase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of CASP1 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]

PMID:29335169 PMID:38705399

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of CAT mRNA

PMID:29335169 PMID:31042592

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine ligand 2

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]

PMID:31042592 PMID:38705399

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

1-Methyl-3-isobutylxanthine promotes the reaction [CFTR protein affects the transport of Water]; CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

cannabinoid receptor 1

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 protein

NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831

G

collagen, type III, alpha 1

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein]

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

complement C3b/C4b receptor 1 like

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein]

NCBI chr 1:194,781,019...194,813,878
Ensembl chr 1:194,779,690...194,813,894

G

corticotropin releasing hormone

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CRH mRNA

NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560

G

cystatin C

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]

NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP1A1 mRNA

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP2E1 mRNA

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

endothelin 1

affects export

EDN1 protein affects the export of Water

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

fibroblast growth factor 2

increases expression

Water results in increased expression of FGF2 mRNA

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GCLC mRNA

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutathione peroxidase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GPX1 mRNA

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione reductase

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GSR mRNA

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

heparin-binding EGF-like growth factor

decreases expression

Water results in decreased expression of HBEGF mRNA

NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858

G

hypocretin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA; AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]

NCBI chr11:100,652,519...100,653,757
Ensembl chr11:100,651,895...100,653,757

G

high mobility group box 1

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

heme oxygenase 1

increases expression
multiple interactions

Water deficiency results in increased expression of HMOX1 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of HMOX1 mRNA

PMID:22060896 PMID:29335169

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hematopoietic prostaglandin D synthase

multiple interactions

Water affects the reaction [Isoquinolines analog binds to and results in decreased activity of HPGDS protein]

NCBI chr 6:65,094,019...65,121,960
Ensembl chr 6:65,094,277...65,121,892

G

interleukin 10

multiple interactions

[Gum Arabic co-treated with Water deficiency co-treated with Diclofenac] results in increased expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]

PMID:29335169 PMID:31042592 PMID:38705399

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

metallothionein 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of MT2 mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NFE2L2 mRNA

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NLR family, pyrin domain containing 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

nitric oxide synthase 2, inducible

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NOS2 mRNA

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

neuropeptide Y

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of NPY mRNA

NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NQO1 mRNA

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

oxytocin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr 2:130,416,432...130,418,974
Ensembl chr 2:130,418,093...130,418,974

G

pro-melanin-concentrating hormone

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA; arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]

NCBI chr10:87,926,934...87,928,236
Ensembl chr10:87,926,934...87,928,237

G

pro-opiomelanocortin-alpha

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]

NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642

G

PYD and CARD domain containing

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

G

solute carrier family 12, member 1

multiple interactions
increases import

[Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water; [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water
SLC12A1 protein results in increased import of Water

NCBI chr 2:124,994,430...125,071,922
Ensembl chr 2:124,994,425...125,071,922

G

solute carrier family 5 (inositol transporters), member 3

increases expression

Water deficiency results in increased expression of SLC5A3 mRNA

NCBI chr16:91,855,210...91,884,361
Ensembl chr16:91,855,210...91,884,361

G

superoxide dismutase 1, soluble

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD1 mRNA

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

increases expression
multiple interactions

Water deficiency results in increased expression of SOD2 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD2 mRNA

PMID:22718889 PMID:29335169

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

sequestosome 1

multiple interactions

[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

tachykinin 1

multiple interactions

TAC1 protein alternative form inhibits the reaction [Cholera Toxin results in increased secretion of Water]; TAC1 protein inhibits the reaction [Cholera Toxin results in increased secretion of Water]

NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834

G

tumor necrosis factor

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]

PMID:31042592 PMID:38705399

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

adrenergic receptor, beta 1

affects expression

Enalaprilat affects the expression of ADRB1 protein

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

adrenergic receptor, beta 2

affects expression

Enalaprilat affects the expression of ADRB2 protein

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

angiotensinogen

decreases expression
multiple interactions

Enalaprilat results in decreased expression of AGT protein modified form
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]

PMID:16452552 PMID:21795644

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

B cell leukemia/lymphoma 2

increases expression

Enalaprilat results in increased expression of BCL2 mRNA

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

bradykinin receptor, beta 1

multiple interactions
increases activity

bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]

NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687

G

endothelin 1

decreases secretion

Enalaprilat results in decreased secretion of EDN1 protein

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

fibronectin 1

decreases expression
multiple interactions

Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein
Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]

PMID:14520012 PMID:21795644

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

glutamate dehydrogenase 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]

NCBI chr14:34,032,684...34,066,990
Ensembl chr14:34,032,684...34,067,222

G

glutamate receptor, metabotropic 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of GRM1 mRNA]

NCBI chr10:10,561,803...10,958,126
Ensembl chr10:10,561,803...10,958,100

G

high mobility group box 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

insulin II

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

peroxisome proliferator activator receptor delta

multiple interactions

[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA

NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448

G

renin 1 structural

increases expression

Enalaprilat results in increased expression of REN mRNA

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

decreases expression

Enalaprilat results in decreased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions
increases uptake

verlukast inhibits the reaction [SLC22A8 protein results in increased uptake of Enalaprilat]

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

transforming growth factor, beta 1

decreases expression

Enalaprilat results in decreased expression of TGFB1 mRNA; Enalaprilat results in decreased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

toll-like receptor 4

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of TLR4 mRNA]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

decreases expression

Enalaprilat results in decreased expression of TNF mRNA

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

gadodiamide hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

decreases expression

gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

thymoma viral proto-oncogene 1

increases phosphorylation
multiple interactions

gadodiamide results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

aldehyde dehydrogenase family 1, subfamily A1

increases expression

gadodiamide results in increased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

ankyrin repeat domain 22

increases expression

gadodiamide results in increased expression of ANKRD22 mRNA

NCBI chr19:34,099,949...34,143,441
Ensembl chr19:34,098,869...34,143,453

G

ataxia telangiectasia mutated

increases expression

gadodiamide results in increased expression of ATM mRNA

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

G

ATPase, class I, type 8B, member 1

increases expression

gadodiamide results in increased expression of ATP8B1 mRNA

NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338

G

C-C motif chemokine ligand 2

increases expression
increases secretion

gadodiamide results in increased expression of CCL2 mRNA
gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein
gadodiamide results in increased secretion of CCL2 protein

PMID:20938346 PMID:20959327

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 4

increases expression

gadodiamide results in increased expression of CCL4 protein

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 7

increases expression

gadodiamide results in increased expression of CCL7 protein

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

C-C motif chemokine ligand 8

increases secretion
increases expression

gadodiamide results in increased secretion of CCL8 protein
gadodiamide results in increased expression of CCL8 mRNA

NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625

G

centrosomal protein 15

increases expression

gadodiamide results in increased expression of CEP15 mRNA

NCBI chr14:10,147,278...10,185,610
Ensembl chr14:10,166,532...10,185,590
Ensembl chr14:10,166,532...10,185,590

G

C-X-C motif chemokine ligand 10

increases expression
increases secretion

gadodiamide results in increased expression of CXCL10 mRNA
gadodiamide results in increased expression of CXCL10 protein
gadodiamide results in increased secretion of CXCL10 protein

PMID:20938346 PMID:20959327

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

chemokine (C-X-C motif) ligand 11

increases secretion
increases expression

gadodiamide results in increased secretion of CXCL11 protein
gadodiamide results in increased expression of CXCL11 mRNA

NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344

G

C-X-C motif chemokine ligand 12

increases expression

gadodiamide results in increased expression of CXCL12 mRNA

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 9

increases expression

gadodiamide results in increased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

fatty acid binding protein 4, adipocyte

decreases expression

gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

indoleamine 2,3-dioxygenase 1

increases expression

gadodiamide results in increased expression of IDO1 mRNA

NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025

G

interferon-induced protein 44 like

increases expression

gadodiamide results in increased expression of IFI44L mRNA

NCBI chr 3:151,464,374...151,468,528
Ensembl chr 3:151,464,374...151,468,529

G

interferon-induced protein with tetratricopeptide repeats 3

increases expression

gadodiamide results in increased expression of IFIT3 mRNA

NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131

G

interferon gamma

increases expression

gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interleukin 13

increases expression

gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein

NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529

G

interleukin 1 alpha

increases expression

gadodiamide results in increased expression of IL1A protein

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 4

increases expression
affects expression

gadodiamide results in increased expression of IL4 protein
gadodiamide affects the expression of IL4 mRNA

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

interleukin 4 induced 1

increases expression

gadodiamide results in increased expression of IL4I1 mRNA

NCBI chr 7:44,485,712...44,490,233
Ensembl chr 7:44,465,811...44,490,233

G

interleukin 6

affects expression
increases expression

gadodiamide affects the expression of IL6 protein
gadodiamide results in increased expression of IL6 mRNA

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

kit ligand

increases expression

gadodiamide results in increased expression of KITLG protein

NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

matrix metallopeptidase 1b (interstitial collagenase)

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]
gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

G

nitric oxide synthase 2, inducible

increases expression

gadodiamide results in increased expression of NOS2 protein

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

neurexophilin and PC-esterase domain family, member 3

increases expression

gadodiamide results in increased expression of NXPE3 mRNA

NCBI chr16:55,660,316...55,717,467
Ensembl chr16:55,660,316...55,715,648

G

peroxisome proliferator activated receptor gamma

decreases expression

gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

increases localization

gadodiamide results in increased localization of RELA protein

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

ras homolog family member Q

increases expression

gadodiamide results in increased expression of RHOQ mRNA

NCBI chr17:87,270,539...87,307,497
Ensembl chr17:87,270,510...87,307,497

G

Ras-like without CAAX 1

increases expression

gadodiamide results in increased expression of RIT1 mRNA

NCBI chr 3:88,624,154...88,638,354
Ensembl chr 3:88,624,145...88,638,356

G

ring finger protein 125

increases expression

gadodiamide results in increased expression of RNF125 mRNA

NCBI chr18:21,077,672...21,120,416
Ensembl chr18:21,077,682...21,116,919

G

radical S-adenosyl methionine domain containing 2

increases expression

gadodiamide results in increased expression of RSAD2 mRNA

NCBI chr12:26,492,742...26,506,451
Ensembl chr12:26,492,745...26,506,451

G

regulator of sex limited protein 1

increases expression

gadodiamide results in increased expression of ZNF595 mRNA

NCBI chr13:67,321,238...67,332,108
Ensembl chr13:67,321,195...67,332,108

G

solute carrier family 39 (zinc transporter), member 10

increases expression

gadodiamide results in increased expression of SLC39A10 mRNA

NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012

G

sialophorin

increases expression

gadodiamide results in increased expression of SPN mRNA

NCBI chr 7:126,731,404...126,743,785
Ensembl chr 7:126,731,404...126,736,995

G

secreted phosphoprotein 1

increases expression

gadodiamide results in increased expression of SPP1 protein

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

transforming growth factor, beta 1

increases expression

gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein

PMID:19404939 PMID:20938346

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tissue inhibitor of metalloproteinase 1

increases expression
multiple interactions

gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]

PMID:19561517 PMID:20938346

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

ubiquitin D

increases expression

gadodiamide results in increased expression of UBD mRNA

NCBI chr17:37,504,783...37,506,992
Ensembl chr17:37,504,783...37,506,986

G

vascular endothelial growth factor A

increases expression

gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein

PMID:19404939 PMID:20938346

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

WD repeat domain 5

increases expression

gadodiamide results in increased expression of WDR5 mRNA

NCBI chr 2:27,405,159...27,426,547
Ensembl chr 2:27,405,169...27,426,547

G

X-linked inhibitor of apoptosis

increases expression

gadodiamide results in increased expression of XIAP mRNA

NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533

G

zinc finger protein 652

increases expression

gadodiamide results in increased expression of ZNF652 mRNA

NCBI chr11:95,639,893...95,655,541
Ensembl chr11:95,603,499...95,725,941

lisinopril dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

Lisinopril analog results in decreased activity of ACE protein

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

increases activity
multiple interactions
increases expression

Lisinopril results in increased activity of ACE2 protein
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased expression of ACE2 mRNA

PMID:15897343 PMID:16221218 PMID:27649628

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acetylcholinesterase

multiple interactions

bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]

PMID:23060470 PMID:31710167

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

angiotensinogen

decreases expression
increases expression
affects response to substance
decreases secretion
increases secretion
multiple interactions
affects metabolic processing

Lisinopril results in decreased expression of AGT protein
Lisinopril results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein

PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More...

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

B cell leukemia/lymphoma 2

decreases expression

Lisinopril results in decreased expression of BCL2

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

CD2-associated protein

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein]

NCBI chr17:43,059,857...43,187,593
Ensembl chr17:43,103,842...43,187,556

G

endothelin 1

decreases secretion

Lisinopril results in decreased secretion of EDN1 protein

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

growth hormone

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

histocompatibility 2, M region locus 3

affects expression

Lisinopril affects the expression of HLA-G mRNA

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

hepatitis A virus cellular receptor 1

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

G

heparanase

multiple interactions

[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]

NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582

G

insulin-like growth factor binding protein 1

increases expression

Lisinopril results in increased expression of IGFBP1 protein

NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546

G

matrix metallopeptidase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

myeloperoxidase

multiple interactions

bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nitric oxide synthase 2, inducible

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nephrosis 1, nephrin

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]

PMID:16636307 PMID:19293598

NCBI chr 7:30,157,259...30,188,048
Ensembl chr 7:30,157,740...30,186,648

G

nephrosis 2, podocin

multiple interactions

Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]

NCBI chr 1:156,138,105...156,155,605
Ensembl chr 1:156,138,297...156,155,605

G

natriuretic peptide type A

decreases expression

Lisinopril results in decreased expression of NPPA protein

NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536

G

renin 1 structural

increases expression
multiple interactions

Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA

PMID:2550029 PMID:8915971 PMID:16221218

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

tissue inhibitor of metalloproteinase 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

vascular endothelial growth factor A

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein]

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

magnesium dihydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214 PMID:22075093

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

cholinergic receptor, nicotinic, alpha polypeptide 4

multiple interactions

Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939

G

C-X-C motif chemokine ligand 10

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein]

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

interleukin 1 beta

multiple interactions

[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:17404311 PMID:18604214 PMID:22075093

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 1 receptor, type I

multiple interactions

IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417

G

interleukin 2

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

G

NLR family, pyrin domain containing 3

multiple interactions

NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

PYD and CARD domain containing

multiple interactions

PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

G

toll-like receptor 4

multiple interactions

TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

mosapride citrate dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anoctamin 1, calcium activated chloride channel

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]

NCBI chr 7:144,142,286...144,305,762
Ensembl chr 7:144,142,286...144,305,711

G

5 hydroxytryptamine (serotonin) receptor 4

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of HTR4 mRNA]

NCBI chr18:62,456,618...62,636,098
Ensembl chr18:62,457,275...62,629,648

G

myosin, light polypeptide kinase

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of MYLK mRNA]

NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790

G

nitric oxide synthase 1, neuronal

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of NOS1 protein]

NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905

G

ryanodine receptor 3

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of RYR3 mRNA]

NCBI chr 2:112,461,699...113,047,755
Ensembl chr 2:112,461,700...113,047,441

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

mosapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

potassium citrate monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

neurofilament, heavy polypeptide

affects expression

Potassium Citrate affects the expression of NEFH mRNA

NCBI chr11:4,888,754...4,898,064
Ensembl chr11:4,888,754...4,898,064

potassium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cofilin 1, non-muscle

increases expression

potassium hydroxide results in increased expression of CFL1 mRNA; potassium hydroxide results in increased expression of CFL1 protein

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

heat shock protein 1

multiple interactions
increases expression

potassium hydroxide results in decreased expression of and affects the localization of HSPB1 protein
potassium hydroxide results in increased expression of HSPB1 mRNA

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

interleukin 1 alpha

multiple interactions

potassium hydroxide results in increased expression of and results in increased secretion of IL1A protein

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

superoxide dismutase 1, soluble

increases expression
decreases expression

potassium hydroxide results in increased expression of SOD1 mRNA
potassium hydroxide results in decreased expression of SOD1 protein

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

royal jelly

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated X protein

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA]
royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]

PMID:30896085 PMID:34227456

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

brain derived neurotrophic factor

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein]

NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352

G

caspase 3

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]

PMID:30896085 PMID:34227456

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 6

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein]

NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752

G

caspase 9

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein]

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catalase

multiple interactions

royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]

PMID:20369241 PMID:30896085 PMID:34227456

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cyclin D1

multiple interactions

royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA]

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cytochrome P450, family 4, subfamily a, polypeptide 14

affects expression

royal jelly affects the expression of CYP4A14 mRNA

NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339

G

E2F transcription factor 1

multiple interactions

royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA]

NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812

G

estrogen receptor 1 (alpha)

multiple interactions
affects binding
increases activity

Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein

PMID:15946813 PMID:17287592

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

multiple interactions
affects binding

Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]

PMID:15946813 PMID:17287592

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

glycogen synthase kinase 3 beta

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein]

NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446

G

insulin I

multiple interactions

royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

myelocytomatosis oncogene

multiple interactions
decreases expression

royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA]
royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]
royal jelly results in decreased expression of MYC mRNA

PMID:27496854 PMID:35099105

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

proliferating cell nuclear antigen

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein]

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

trefoil factor 1

increases expression

royal jelly results in increased expression of TFF1 mRNA

NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251

G

transformation related protein 53

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

vascular endothelial growth factor A

increases expression

royal jelly results in increased expression of VEGFA mRNA

PMID:15946813 PMID:17287592

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-Coenzyme A oxidase 1, palmitoyl

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871

G

acyl-CoA synthetase short-chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr 2:150,460,031...150,510,160
Ensembl chr 2:150,460,025...150,510,420

G

acyl-CoA synthetase short-chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

inhibitor of kappaB kinase beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr11:97,050,536...97,078,718
Ensembl chr11:97,050,540...97,078,707

G

myeloid differentiation primary response gene 88

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477

G

N-acetyltransferase 2 (arylamine N-acetyltransferase)

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr 8:67,947,527...67,955,296
Ensembl chr 8:67,947,510...67,955,236

G

nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr 2:168,318,330...168,443,900
Ensembl chr 2:168,318,330...168,443,577

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

phosphoenolpyruvate carboxykinase 1, cytosolic

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

superoxide dismutase 2, mitochondrial

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

transforming growth factor, beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

toll-like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074

G

toll-like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

UDP glucuronosyltransferase 1 family, polypeptide A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191

sodium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle, aorta

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of ACTA2 protein]

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

caspase 3

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of CASP3 mRNA]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

collagen, type I, alpha 2

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of COL1A2 protein
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of COL1A2 protein]

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type III, alpha 1

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of COL3A1 protein]

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

epidermal growth factor receptor

affects response to substance

EGFR SNP affects the susceptibility to Sodium Hydroxide

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

ezrin

increases expression

Sodium Hydroxide results in increased expression of EZR mRNA

NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183

G

fibronectin 1

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of FN1 protein]

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

histocompatibility 2, M region locus 3

affects response to substance

HLA-G SNP affects the susceptibility to Sodium Hydroxide

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

immediate early response 3

affects response to substance

IER3 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

interleukin 1 beta

increases expression

Sodium Hydroxide results in increased expression of IL1B protein

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 22B

affects response to substance

IL22 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943

G

jun proto-oncogene

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of JUN mRNA]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

potassium channel, subfamily K, member 3

increases activity
decreases response to substance

Sodium Hydroxide results in increased activity of KCNK3 protein
KCNK3 protein mutant form results in decreased susceptibility to Sodium Hydroxide

NCBI chr 5:30,745,514...30,782,614
Ensembl chr 5:30,745,514...30,782,615

G

matrix metallopeptidase 9

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of MMP9 mRNA
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of MMP9 mRNA]

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

plasminogen activator, urokinase

affects response to substance

PLAU SNP affects the susceptibility to Sodium Hydroxide

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

tripartite motif-containing 10

affects response to substance

TRIM10 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr17:37,180,388...37,188,725
Ensembl chr17:37,180,466...37,188,725

G

tripartite motif-containing 31

affects response to substance

TRIM31 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr17:37,209,022...37,221,109
Ensembl chr17:37,209,010...37,221,106

G

tripartite motif-containing 40

affects response to substance

TRIM40 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr17:37,192,488...37,201,049
Ensembl chr17:37,192,490...37,201,015

sodium thiosulfate pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP9 protein]

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

myeloperoxidase

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Tacrolimus results in increased expression of A2M mRNA

NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186

G

ATP-binding cassette, sub-family A member 1

multiple interactions
increases expression

[Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Tacrolimus results in increased expression of ABCA1 mRNA

PMID:17016853 PMID:21865292

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family B member 11

decreases activity

Tacrolimus results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

increases response to substance
decreases activity
affects export
multiple interactions
increases export
affects response to substance

ABCB1 gene SNP results in increased susceptibility to Tacrolimus
Tacrolimus results in decreased activity of ABCB1 protein
ABCB1 protein affects the export of Tacrolimus
[Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]
ABCB1 protein affects the susceptibility to Tacrolimus

PMID:1381629 PMID:11920757 PMID:12352921 PMID:15919446 PMID:15964336 More...

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

acetyl-Coenzyme A acyltransferase 1B

decreases expression

Tacrolimus results in decreased expression of ACAA1B mRNA

NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161

G

acyl-Coenzyme A dehydrogenase, long-chain

decreases expression

Tacrolimus results in decreased expression of ACADL mRNA

NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436

G

angiotensin converting enzyme 2

decreases expression

Tacrolimus results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acid phosphatase 5, tartrate resistant

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]

NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007

G

actin alpha 2, smooth muscle, aorta

increases expression

Tacrolimus results in increased expression of ACTA2 protein

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

activin A receptor, type 1B

multiple interactions

[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]

NCBI chr15:101,071,953...101,111,565
Ensembl chr15:101,071,948...101,111,565

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

increases expression

Tacrolimus results in increased expression of ADAMTS1 mRNA

NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

increases expression

Tacrolimus results in increased expression of ADAMTS2 mRNA

NCBI chr11:50,492,912...50,698,400
Ensembl chr11:50,492,911...50,698,400

G

adenylate cyclase 9

multiple interactions

Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]]

NCBI chr16:4,102,750...4,255,094
Ensembl chr16:4,105,393...4,238,362

G

adrenergic receptor, alpha 1d

increases expression

Tacrolimus results in increased expression of ADRA1D mRNA

NCBI chr 2:131,387,277...131,404,417
Ensembl chr 2:131,387,770...131,404,203

G

allograft inflammatory factor 1

increases expression

Tacrolimus results in increased expression of AIF1 mRNA

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

aldehyde dehydrogenase family 1, subfamily A1

decreases expression

Tacrolimus results in decreased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A7

decreases expression

Tacrolimus results in decreased expression of ALDH1A7 mRNA

NCBI chr19:20,670,318...20,704,920
Ensembl chr19:20,670,317...20,704,926

G

aldehyde dehydrogenase 2, mitochondrial

decreases expression

Tacrolimus results in decreased expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase 9, subfamily A1

decreases expression

Tacrolimus results in decreased expression of ALDH9A1 mRNA

NCBI chr 1:167,177,560...167,196,100
Ensembl chr 1:167,177,560...167,196,101

G

ALG3 alpha-1,3- mannosyltransferase

decreases expression

Tacrolimus results in decreased expression of ALG3 mRNA

NCBI chr16:20,424,208...20,429,515
Ensembl chr16:20,424,124...20,430,485

G

angiopoietin-like 6

increases expression

Tacrolimus results in increased expression of ANGPTL6 mRNA

NCBI chr 9:20,785,104...20,791,116
Ensembl chr 9:20,785,104...20,791,023

G

ankyrin repeat domain 1

increases expression

Tacrolimus results in increased expression of ANKRD1 mRNA

NCBI chr19:36,089,365...36,097,244
Ensembl chr19:36,089,361...36,097,499

G

ankyrin repeat domain 34A

decreases expression

Tacrolimus results in decreased expression of ANKRD34A mRNA

NCBI chr 3:96,503,599...96,507,442
Ensembl chr 3:96,503,952...96,507,091

G

alanyl aminopeptidase, membrane

increases secretion

Tacrolimus results in increased secretion of ANPEP protein

NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807

G

annexin A1

increases expression

Tacrolimus results in increased expression of ANXA1

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

amine oxidase, copper-containing 1

increases expression

Tacrolimus results in increased expression of AOC1 mRNA

NCBI chr 6:48,872,189...48,886,122
Ensembl chr 6:48,849,830...48,886,122

G

amphiregulin

increases expression

Tacrolimus results in increased expression of AREG mRNA

NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291

G

ARF related protein 1

increases expression

Tacrolimus results in increased expression of ARFRP1 mRNA

NCBI chr 2:180,999,483...181,007,197
Ensembl chr 2:180,999,483...181,007,197

G

Rho GTPase activating protein 45

increases expression

Tacrolimus results in increased expression of ARHGAP45 mRNA

NCBI chr10:79,852,505...79,867,305
Ensembl chr10:79,852,487...79,867,306

G

Rho guanine nucleotide exchange factor 11

increases expression

Tacrolimus results in increased expression of ARHGEF11 mRNA

NCBI chr 3:87,524,855...87,645,346
Ensembl chr 3:87,524,866...87,645,341

G

actin related protein 2/3 complex, subunit 5

increases expression

Tacrolimus results in increased expression of ARPC5 mRNA

NCBI chr 1:152,642,293...152,651,331
Ensembl chr 1:152,642,293...152,651,348

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

Tacrolimus results in increased expression of ARV1 mRNA

NCBI chr 8:125,448,765...125,469,533
Ensembl chr 8:125,448,878...125,460,862

G

ASXL transcriptional regulator 3

decreases expression

Tacrolimus results in decreased expression of ASXL3 mRNA

NCBI chr18:22,477,195...22,663,284
Ensembl chr18:22,477,303...22,663,072

G

activating transcription factor 3

increases expression

Tacrolimus results in increased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

activating transcription factor 4

increases expression

Tacrolimus results in increased expression of ATF4 mRNA

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

G

activating transcription factor 6

increases expression

Tacrolimus results in increased expression of ATF6 mRNA

NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

decreases expression

Tacrolimus results in decreased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Na+/K+ transporting, beta 3 polypeptide

decreases expression

Tacrolimus results in decreased expression of ATP1B3 mRNA

NCBI chr 9:96,214,708...96,246,368
Ensembl chr 9:96,214,708...96,246,495

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

increases expression

Tacrolimus results in increased expression of ATP2A2 mRNA

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

beta-2 microglobulin

increases expression

Tacrolimus results in increased expression of B2M mRNA

NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564

G

BCL2-associated agonist of cell death

multiple interactions

Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]

PMID:15036616 PMID:15280438

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

basic leucine zipper transcription factor, ATF-like 3

increases expression

Tacrolimus results in increased expression of BATF3 mRNA

NCBI chr 1:190,830,611...190,841,140
Ensembl chr 1:190,830,044...190,841,142

G

BCL2-associated X protein

multiple interactions
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]
Tacrolimus results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein

PMID:10205001 PMID:15571979 PMID:27606422 PMID:35033536

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]
Tacrolimus results in decreased expression of BCL2 protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein
Tacrolimus results in increased expression of BCL2 protein

PMID:10205001 PMID:15571979 PMID:27606422

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2-like 1

multiple interactions

Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein]

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

B cell leukemia/lymphoma 3

increases expression

Tacrolimus results in increased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

brain derived neurotrophic factor

multiple interactions

Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]; Tacrolimus promotes the reaction [U 0126 inhibits the reaction [decamethrin results in increased expression of BDNF exon]]; U 0126 promotes the reaction [Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]]

NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352

G

baculoviral IAP repeat-containing 3

increases expression

Tacrolimus results in increased expression of BIRC3 mRNA

NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187

G

baculoviral IAP repeat-containing 5

decreases expression

Tacrolimus results in decreased expression of BIRC5 mRNA

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

bone morphogenetic protein 7

multiple interactions
decreases expression

Ramipril inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]; valsartan inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

BTG anti-proliferation factor 2

increases expression

Tacrolimus results in increased expression of BTG2 mRNA

NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858

G

butyrophilin-like 9

decreases expression

Tacrolimus results in decreased expression of BTNL9 mRNA

NCBI chr11:49,059,152...49,077,916
Ensembl chr11:49,056,412...49,077,986

G

complement component 1, q subcomponent, alpha polypeptide

increases expression

Tacrolimus results in increased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, beta polypeptide

increases expression

Tacrolimus results in increased expression of C1QB mRNA

NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498

G

complement component 1, q subcomponent, C chain

increases expression

Tacrolimus results in increased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

complement component 1, r subcomponent A

increases expression

Tacrolimus results in increased expression of C1RA mRNA

NCBI chr 6:124,489,580...124,500,399
Ensembl chr 6:124,489,364...124,500,402

G

complement C2

increases expression

Tacrolimus results in increased expression of C2 mRNA

NCBI chr17:35,081,578...35,101,076
Ensembl chr17:35,081,580...35,117,241

G

complement component 3

increases expression

Tacrolimus results in increased expression of C3 mRNA

PMID:21865292 PMID:29362864

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

complement C4B (Chido blood group)

increases expression

Tacrolimus results in increased expression of C4B mRNA

NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856

G

calbindin 1

decreases expression

Tacrolimus results in decreased expression of CALB1 mRNA; Tacrolimus results in decreased expression of CALB1 protein

PMID:14978156 PMID:21865292

NCBI chr 4:15,881,264...15,906,709
Ensembl chr 4:15,881,264...15,908,064

G

calcitonin receptor

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]

NCBI chr 6:3,685,678...3,764,713
Ensembl chr 6:3,685,680...3,764,714

G

calreticulin

increases expression

Tacrolimus results in increased expression of CALR mRNA

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

calcium/calmodulin-dependent protein kinase ID

increases expression

Tacrolimus results in increased expression of CAMK1D mRNA

NCBI chr 2:5,298,268...5,719,665
Ensembl chr 2:5,298,268...5,719,326

G

capping actin protein, gelsolin like

increases expression

Tacrolimus results in increased expression of CAPG mRNA

NCBI chr 6:72,515,265...72,539,966
Ensembl chr 6:72,521,374...72,539,966

G

caspase 3

multiple interactions
increases cleavage
increases activity

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
Tacrolimus results in increased cleavage of CASP3 protein
Tacrolimus results in increased activity of CASP3 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]

PMID:10205001 PMID:12642403 PMID:12871656 PMID:12892836 PMID:15207740 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
Tacrolimus results in increased expression of CASP8 protein

PMID:15548389 PMID:27606422

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]
Tacrolimus results in increased expression of CASP9 protein

PMID:15548389 PMID:27606422

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catalase

increases expression
decreases response to substance

Tacrolimus results in increased expression of CAT protein
CAT protein results in decreased susceptibility to Tacrolimus

PMID:14675044 PMID:18766458

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

Casitas B-lineage lymphoma-like 1

increases expression

Tacrolimus results in increased expression of CBLL1 mRNA

NCBI chr12:31,534,828...31,550,536
Ensembl chr12:31,534,828...31,549,615

G

coiled-coil domain containing 88B

increases expression

Tacrolimus results in increased expression of CCDC88B mRNA

NCBI chr19:6,821,991...6,835,586
Ensembl chr19:6,821,991...6,835,579

G

C-C motif chemokine ligand 11

decreases expression

Tacrolimus results in decreased expression of CCL11 mRNA

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 17

increases expression

Tacrolimus results in increased expression of CCL17 mRNA

NCBI chr 8:95,535,996...95,538,666
Ensembl chr 8:95,537,081...95,538,664

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]
pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]

PMID:12472797 PMID:23958496 PMID:29362864 PMID:36416909

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 20

increases expression

Tacrolimus results in increased expression of CCL20 mRNA

NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888

G

C-C motif chemokine ligand 3

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 5

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CCL5 mRNA
Tacrolimus results in increased expression of CCL5 mRNA
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]

PMID:15948978 PMID:23958496 PMID:25270620

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine ligand 6

increases expression

Tacrolimus results in increased expression of CCL6 mRNA

PMID:21865292 PMID:29362864

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

C-C motif chemokine ligand 7

increases expression

Tacrolimus results in increased expression of CCL7 mRNA

PMID:23958496 PMID:29362864

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

C-C motif chemokine ligand 8

increases expression

Tacrolimus results in increased expression of CCL8 mRNA

NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625

G

cellular communication network factor 2

multiple interactions

Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

cyclin A2

increases expression

Tacrolimus results in increased expression of CCNA2 mRNA

NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299

G

cyclin B2

decreases expression
increases expression

Tacrolimus results in decreased expression of CCNB2 mRNA
Tacrolimus results in increased expression of CCNB2 mRNA

PMID:16574167 PMID:29362864

NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829

G

C-C motif chemokine receptor 2

increases expression

Tacrolimus results in increased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-C motif chemokine receptor 3

decreases expression

Tacrolimus results in decreased expression of CCR3 mRNA

NCBI chr 9:123,817,799...123,831,729
Ensembl chr 9:123,822,009...123,831,726

G

C-C motif chemokine receptor-like 2

increases expression

Tacrolimus results in increased expression of CCRL2 mRNA

NCBI chr 9:110,883,902...110,886,586
Ensembl chr 9:110,883,554...110,886,587

G

CD2 antigen

multiple interactions

Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]

NCBI chr 3:101,183,224...101,195,255
Ensembl chr 3:101,183,215...101,195,255

G

CD44 antigen

increases expression

Tacrolimus results in increased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD68 antigen

increases expression

Tacrolimus results in increased expression of CD68 mRNA

NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979

G

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)

increases expression

Tacrolimus results in increased expression of CD74 mRNA

NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724

G

CD80 antigen

decreases expression

Tacrolimus results in decreased expression of CD80 protein

NCBI chr16:38,277,793...38,316,682
Ensembl chr16:38,275,923...38,316,697

G

CD83 antigen

increases expression

Tacrolimus results in increased expression of CD83 mRNA

NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608

G

CD86 antigen

decreases expression

Tacrolimus results in decreased expression of CD86 protein

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cell division cycle associated 3

increases expression

Tacrolimus results in increased expression of CDCA3 mRNA

NCBI chr 6:124,806,533...124,810,664
Ensembl chr 6:124,806,510...124,810,664

G

cell division cycle associated 5

increases expression

Tacrolimus results in increased expression of CDCA5 mRNA

NCBI chr19:6,135,127...6,141,803
Ensembl chr19:6,135,013...6,141,807

G

cell division cycle associated 8

increases expression

Tacrolimus results in increased expression of CDCA8 mRNA

NCBI chr 4:124,812,258...124,830,710
Ensembl chr 4:124,812,258...124,833,104

G

cadherin 1

decreases expression

Tacrolimus results in decreased expression of CDH1 protein

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 11

increases expression

Tacrolimus results in increased expression of CDH11 mRNA

NCBI chr 8:103,358,727...103,512,125
Ensembl chr 8:103,358,727...103,512,274

G

cadherin 16

decreases expression

Tacrolimus results in decreased expression of CDH16 mRNA

NCBI chr 8:105,328,547...105,351,028
Ensembl chr 8:105,328,543...105,351,028

G

cyclin dependent kinase inhibitor 1B

increases expression

Tacrolimus results in increased expression of CDKN1B mRNA

NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476

G

CCAAT/enhancer binding protein alpha

increases expression

Tacrolimus results in increased expression of CEBPA mRNA

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

G

centromere protein W

increases expression

Tacrolimus results in increased expression of CENPW mRNA

NCBI chr10:30,072,005...30,076,599
Ensembl chr10:30,070,565...30,076,556

G

complement component factor i

increases expression

Tacrolimus results in increased expression of CFI mRNA

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

cytoskeleton associated protein 2

increases expression

Tacrolimus results in increased expression of CKAP2 mRNA

NCBI chr 8:22,658,168...22,675,835
Ensembl chr 8:22,658,176...22,675,835

G

cytoskeleton-associated protein 4

increases expression

Tacrolimus results in increased expression of CKAP4 mRNA

NCBI chr10:84,362,169...84,369,752
Ensembl chr10:84,362,169...84,369,926

G

claudin 1

decreases expression

Tacrolimus results in decreased expression of CLDN1 mRNA

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

claudin 4

increases expression

Tacrolimus results in increased expression of CLDN4 mRNA

NCBI chr 5:134,973,977...134,975,788
Ensembl chr 5:134,973,973...134,975,788

G

claudin 7

increases expression

Tacrolimus results in increased expression of CLDN7 mRNA

NCBI chr11:69,855,605...69,858,712
Ensembl chr11:69,855,605...69,858,711

G

C-type lectin domain family 7, member a

increases expression

Tacrolimus results in increased expression of CLEC7A mRNA

NCBI chr 6:129,438,554...129,449,748
Ensembl chr 6:129,438,554...129,449,742

G

CDC-like kinase 3

increases expression

Tacrolimus results in increased expression of CLK3 mRNA

NCBI chr 9:57,657,904...57,672,397
Ensembl chr 9:57,657,907...57,673,143

G

clusterin

increases expression

Tacrolimus results in increased expression of CLU mRNA

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

cochlin

increases expression

Tacrolimus results in increased expression of COCH mRNA

NCBI chr12:51,640,156...51,652,558
Ensembl chr12:51,640,124...51,652,554

G

collagen, type I, alpha 1

increases expression

Tacrolimus results in increased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

increases expression

Tacrolimus results in increased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type III, alpha 1

increases expression

Tacrolimus results in increased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

COP9 signalosome subunit 8

increases expression

Tacrolimus results in increased expression of COPS8 mRNA

NCBI chr 1:90,531,147...90,541,063
Ensembl chr 1:90,530,703...90,541,063

G

ceruloplasmin

increases expression

Tacrolimus results in increased expression of CP mRNA

NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309

G

cAMP responsive element binding protein 3-like 3

decreases expression

Tacrolimus results in decreased expression of CREB3L3 mRNA

NCBI chr10:80,920,163...80,934,706
Ensembl chr10:80,920,158...80,934,708

G

cysteine-rich with EGF-like domains 2

increases expression

Tacrolimus results in increased expression of CRELD2 mRNA

NCBI chr15:88,703,849...88,710,884
Ensembl chr15:88,703,849...88,710,886

G

colony stimulating factor 1 (macrophage)

increases expression

Tacrolimus results in increased expression of CSF1 mRNA

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

colony stimulating factor 2 (granulocyte-macrophage)

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CSF2 protein
Tacrolimus results in increased expression of CSF2 mRNA
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein]

PMID:1376361 PMID:11407316 PMID:23958496

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)

increases expression

Tacrolimus results in increased expression of CSF2RB2 mRNA

NCBI chr15:78,166,707...78,189,921
Ensembl chr15:78,166,707...78,189,921

G

cathepsin L

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTSL protein]
Tacrolimus results in increased expression of CTSL mRNA

PMID:18172886 PMID:21865292 PMID:25270620

NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704

G

C-X-C motif chemokine ligand 10

increases expression

Tacrolimus results in increased expression of CXCL10 mRNA

PMID:21865292 PMID:23958496 PMID:25270620

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

chemokine (C-X-C motif) ligand 11

increases expression

Tacrolimus results in increased expression of CXCL11 mRNA

NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344

G

C-X-C motif chemokine ligand 15

multiple interactions

Tacrolimus inhibits the reaction [cinnamaldehyde results in increased expression of CXCL8 mRNA]; Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL8 protein]; Tacrolimus inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CXCL8 mRNA]

PMID:20090409 PMID:36416909

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome b-245, alpha polypeptide

multiple interactions
increases expression

Ramipril inhibits the reaction [Tacrolimus results in increased expression of CYBA mRNA]

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome P450, family 27, subfamily b, polypeptide 1

increases expression

Tacrolimus results in increased expression of CYP27B1 mRNA

NCBI chr10:126,884,115...126,891,897
Ensembl chr10:126,884,119...126,888,875

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions

CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]

PMID:15010519 PMID:15285851 PMID:17377957

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 3, subfamily a, polypeptide 13

affects metabolic processing
decreases methylation
multiple interactions
affects response to substance

CYP3A5 gene polymorphism affects the metabolism of Tacrolimus; CYP3A5 gene SNP affects the metabolism of Tacrolimus; CYP3A5 protein affects the metabolism of Tacrolimus; CYP3A5 protein polymorphism affects the metabolism of Tacrolimus
CYP3A5 protein results in decreased methylation of Tacrolimus
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]
CYP3A5 gene affects the susceptibility to Tacrolimus; CYP3A5 polymorphism affects the susceptibility to Tacrolimus

PMID:15502717 PMID:15723604 PMID:15729180 PMID:15808586 PMID:15919447 More...

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

decorin

increases expression

Tacrolimus results in increased expression of DCN mRNA

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
Tacrolimus results in increased expression of DDIT3 mRNA

PMID:23958496 PMID:25270620

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

DNA-damage-inducible transcript 4-like

decreases expression

Tacrolimus results in decreased expression of DDIT4L mRNA

NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094

G

24-dehydrocholesterol reductase

decreases expression

Tacrolimus results in decreased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G